Inveltys Patent Expiration

Inveltys is a drug owned by Alcon Laboratories Inc. It is protected by 12 US drug patents filed from 2019 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 03, 2033. Details of Inveltys's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056057 Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

Active
US9532955 Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

Active
US10058511 Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

Active
US11219597 Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

Active
US10864219 Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

Active
US9737491 Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

Active
US9827191 Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

Active
US10688045 Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

Active
US11642317 Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

Active
US10646437 Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

Active
US9393213 Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

Active
US11872318 Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Inveltys's patents.

Given below is the list of recent legal activities going on the following patents of Inveltys.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 19 Jun, 2024 US9532955
Payment of Maintenance Fee, 4th Year, Large Entity 29 May, 2024 US10864219
Correspondence Address Change 25 Mar, 2024 US10058511
Correspondence Address Change 25 Mar, 2024 US9532955
Correspondence Address Change 04 Mar, 2024 US11872318
Email Notification 16 Jan, 2024 US11872318
Patent Issue Date Used in PTA Calculation 16 Jan, 2024 US11872318
Patent eGrant Notification 16 Jan, 2024 US11872318
Mail Patent eGrant Notification 16 Jan, 2024 US11872318
Recordation of Patent eGrant 16 Jan, 2024 US11872318


FDA has granted several exclusivities to Inveltys. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Inveltys, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Inveltys.

Exclusivity Information

Inveltys holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Inveltys's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 22, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Inveltys is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Inveltys's family patents as well as insights into ongoing legal events on those patents.

Inveltys's Family Patents

Inveltys has patent protection in a total of 12 countries. It's US patent count contributes only to 35.9% of its total global patent coverage. Click below to unlock the full patent family tree for Inveltys.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Inveltys's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 03, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Inveltys Generics:

Loteprednol Etabonate is the generic name for the brand Inveltys. 5 different companies have already filed for the generic of Inveltys, with Sentiss having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Inveltys's generic

Alternative Brands for Inveltys

Inveltys which is used for treating inflammation and various disorders in the eye., has several other brand drugs in the same treatment category and using the same active ingredient (Loteprednol Etabonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Alcon Labs Inc
Eysuvis

(uses Loteprednol Etabonate)

Used for treating dry eye condition.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Loteprednol Etabonate. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Bausch And Lomb
Alrex
Lotemax
Zylet
Bausch And Lomb Inc
Lotemax
Lotemax Sm
Pharmos
Lotemax


Apart from brand drugs containing the same ingredient, some generics have also been filed for Loteprednol Etabonate, Inveltys's active ingredient. Check the complete list of approved generic manufacturers for Inveltys





About Inveltys

Inveltys is a drug owned by Alcon Laboratories Inc. It is used for treating inflammation and various disorders in the eye. Inveltys uses Loteprednol Etabonate as an active ingredient. Inveltys was launched by Alcon Labs Inc in 2018.

Approval Date:

Inveltys was approved by FDA for market use on 22 August, 2018.

Active Ingredient:

Inveltys uses Loteprednol Etabonate as the active ingredient. Check out other Drugs and Companies using Loteprednol Etabonate ingredient

Treatment:

Inveltys is used for treating inflammation and various disorders in the eye.

Dosage:

Inveltys is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
1% SUSPENSION/DROPS Prescription OPHTHALMIC